Krystal Biotech, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Krystal Biotech, Inc. specializes in the development and commercialization of genetic medicines, focusing on redosable gene therapies for severe, life-threatening, or rare diseases, primarily in dermatology. Its core product is VYJUVEK (beremagene geperpavec-svdt), the first and only redosable gene therapy approved for treating dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The company employs its proprietary STAR-D platform, which uses a genetically modified, non-replicating herpes simplex virus type 1 (HSV-1) vector to deliver therapeutic genes directly to skin cells. Krystal's product and pipeline extend into additional severe dermatological diseases, and it is advancing gene therapy candidates targeting ocular complications of DEB and other inherited retinal diseases, respiratory conditions including cystic fibrosis, and oncology indications such as non-small cell lung cancer (NSCLC). Recent major developments include FDA approval for expanded labeling of VYJUVEK, allowing treatment of newborns and enabling self-application by patients and caregivers, which broadens patient access. The FDA also granted platform technology designation to Krystal’s HSV-1 vector used in KB801, an investigational gene therapy for neurotrophic keratitis, potentially streamlining development and regulatory review processes. The company is progressing clinical trials across multiple fronts: KB801 for ocular diseases, KB708 and KB707 in oncology with a focus on inhaled delivery for solid tumors, and KB408 for alpha-1 antitrypsin deficiency. Krystal reported strong financial performance with high-margin VYJUVEK revenue and expanded global launches in Japan and Europe. In 2024, it completed the sale of its Rare Pediatric Disease Priority Review Voucher for $100 million. Additionally, institutional investors such as State Street Corporation have recently increased holdings in Krystal, reflecting growing market confidence. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech operates globally with a commercial presence in the United States, Japan, Germany, and France. Its business segments cover gene therapies for dermatology, respiratory diseases, ophthalmology, and oncology. The company maintains a robust development pipeline, investing significantly in research and clinical programs to expand therapeutic applications of its HSV-1 gene delivery platform. This comprehensive approach positions Krystal Biotech as a leader in redosable gene therapy innovation, targeting rare genetic diseases with limited or no approved treatment options and pursuing strategic clinical and regulatory milestones to broaden its commercial footprint and therapeutic scope.
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
3 Soaring Stocks That May Have More Upside Ahead
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
3 Biotech Firms With Major Potential Catalysts in the Coming Months
3 Biotech Firms With Major Potential Catalysts in the Coming Months
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This Profitable Biotech Stealthily Climbs Into A Buy Zone
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus